140 related articles for article (PubMed ID: 11055154)
1. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
Ben-Asher D; Juris M
J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
[No Abstract] [Full Text] [Related]
2. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
Whitener MD
Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
[No Abstract] [Full Text] [Related]
3. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
4. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
5. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
6. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
Margolis RE
Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
[No Abstract] [Full Text] [Related]
7. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
8. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
9. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A
Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
[No Abstract] [Full Text] [Related]
10. Hoechst plans divestitures to gain FTC nod.
Scott L
Mod Healthc; 1995 Sep; 25(39):32. PubMed ID: 10151416
[No Abstract] [Full Text] [Related]
11. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
12. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
Sinha MS; Curfman GD; Carrier MA
JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
[No Abstract] [Full Text] [Related]
13. Bundling patented drugs and medical services: an antitrust analysis.
Hurwitz MA
Spec Law Dig Health Care Law; 1992 Jan; (155):7-39. PubMed ID: 10115664
[No Abstract] [Full Text] [Related]
14. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
15. Will antitrust cops bust billion-dollar drug deals?
Barnett AA
J Am Health Care; 1994; 4(5):5-7. PubMed ID: 10142816
[No Abstract] [Full Text] [Related]
16. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
Steinhauer EH
Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
[No Abstract] [Full Text] [Related]
17. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
Hawkes N
BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
[No Abstract] [Full Text] [Related]
18. SEC going after insider trading based on medical research results. Securities Exchange Commission.
Skolnick AA
JAMA; 1998 Jul; 280(1):10-1. PubMed ID: 9660347
[No Abstract] [Full Text] [Related]
19. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
Rea TS
Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
[No Abstract] [Full Text] [Related]
20. Matching prescription drugs and consumers. The benefits of direct advertising.
Masson A; Rubin PH
N Engl J Med; 1985 Aug; 313(8):513-5. PubMed ID: 4022085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
